Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1548-1561

  Halberstadt, Adam L ^a   Koedood, Liselore ^a   Powell, Susan B ^a   Geyer, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hallucinogen; head twitch response; knockout; locomotor activity; mice; obsessive compulsive disorder; psilocin; psilocybin; serotonin

Indexed keywords

1 METHYLPSILOCIN; 5 METHOXY N,N DIMETHYLTRYPTAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PSILOCIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENE DELETION; HEAD TWITCH; LOCOMOTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY;

ANIMALS; BEHAVIOR; HALLUCINOGENS; MALE; METHOXYDIMETHYLTRYPTAMINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PIPERAZINES; PSILOCYBINE; PYRIDINES; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 83455213094     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110388326     Document Type: Article

References (63)

1. Adams LM, Geyer MA. Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry. 1985 ; 9: 121-132 (Pubitemid 15089220)
2. Berendsen HH, Jenck F, Broekkamp CL. Selective activation of 5HT1A receptors induces lower lip retraction in the rat. Pharmacol Biochem Behav. 1989 ; 33: 821-827 (Pubitemid 19284295)
3. Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, et al. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 ; 43: 4701-4710
4. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005a ; 17: 1497-1508 (Pubitemid 41510955)
5. Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl). 2007 ; 195: 415-424 (Pubitemid 350161767)
6. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. NeuroReport. 2004 ; 15: 1947-1951 (Pubitemid 39180619)
7. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, et al. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology. 2005b ; 30: 1154-1162 (Pubitemid 40720974)
8. Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967 ; 11: 65-78
9. Darmani NA, Martin BR, Pandey U, Glennon RA. Do functional relationships exist between 5-HT1A and 5-HT2 receptors?. Pharmacol Biochem Behav. 1990 ; 36: 901-906 (Pubitemid 20272314)
10. Eison AS, Wright RN. 5-HT1A and 5-HT2 receptors mediate discrete behaviors in the Mongolian gerbil. Pharmacol Biochem Behav. 1992 ; 43: 131-137
11. Eivindvik K, Rasmussen KE, Sund RB. Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon. Acta Pharm Nord. 1989 ; 1: 295-302 (Pubitemid 20010877)
12. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, et al. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl). 2005 ; 181: 496-503 (Pubitemid 41480898)
13. Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, et al. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav. 2006 ; 83: 122-129
14. Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav. 2008 ; 88: 358-365 (Pubitemid 350123552)
15. Geyer MA, Light RK, Rose GJ, Petersen LR, Horwitt DD, Adams LM, et al. A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology (Berl). 1979 ; 65: 35-40 (Pubitemid 10222234)
16. Geyer MA, Russo PV, Masten VL. Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses. Pharmacol Biochem Behav. 1986 ; 25: 277-288 (Pubitemid 16040937)
17. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007 ; 53: 439-452 (Pubitemid 46161267)
18. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci. 2003 ; 23: 8836-8843 (Pubitemid 37210895)
19. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, et al. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol. 1998 ; 9: 561-566 (Pubitemid 28552549)
20. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl). 1999 ; 142: 41-50 (Pubitemid 29196062)
21. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 ; 187: 268-283 (Pubitemid 44088380)
22. Grob CS, Danforth AL, Chopra GS, Hagerty MC, Halberstadt AL, McKay CR. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2010 ;:
23. Halberstadt AL, Geyer MA Encyclopedia of Behavioral Neuroscience. Koob G Thompson R Moal ML, ed. London: Academic Press ; 2010: 12-20.
24. Halberstadt AL, Nichols DE Handbook of the Behavioral Neurobiology of Serotonin. Muller C Jacobs B, ed. London: Academic ; 2010: 621-636.
25. Halberstadt AL, Buell MR, Masten VL, Risbrough VB, Geyer MA. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl). 2008 ; 201: 55-66
26. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA, et al. 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009 ; 34: 1958-1967
27. Hasler F, Bourquin D, Brenneisen R, Bar T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997 ; 72: 175-184 (Pubitemid 27246716)
28. Horita A, Weber LJ. Dephosphorylation of psilocybin to psilocin by alkaline phosphatase. Proc Soc Exp Biol Med. 1961a ; 106: 32-34
29. Horita A, Weber LJ. The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol. 1961b ; 7: 47-54
30. Johnson MP, Loncharich RJ, Baez M, Nelson DL. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 ; 45: 277-286 (Pubitemid 24063081)
31. Krebs KM, Geyer MA. Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology (Berl). 1994 ; 113: 429-437 (Pubitemid 24150490)
32. Krebs-Thomson K, Geyer MA. The role of 5-HT(1A) receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats. Behav Pharmacol. 1996 ; 7: 551-559
33. Krebs-Thomson K, Paulus MP, Geyer MA. Effects of hallucinogens on locomotor and investigatory activity and patterns: Influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology. 1998 ; 18: 339-351 (Pubitemid 28140659)
34. Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl). 2006 ; 189: 319-329 (Pubitemid 44772815)
35. Li JX, Rice KC, France CP. Behavioral effects of dipropyltryptamine in rats: Evidence for 5-HT1A and 5-HT2A agonist activity. Behav Pharmacol. 2007 ; 18: 283-288 (Pubitemid 46884164)
36. Lucki I, Nobler MS, Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther. 1984 ; 228: 133-139 (Pubitemid 14223392)
37. McKenna DJ, Repke DB, Lo L, Peroutka SJ. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 1990 ; 29: 193-198 (Pubitemid 20096380)
38. Mittman SM, Geyer MA. Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology (Berl). 1991 ; 105: 69-76
39. Moreno FA, Delgado PL. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry. 1997 ; 154: 1037-1038
40. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 ; 67: 1735-1740 (Pubitemid 44955154)
41. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181 (Pubitemid 38167565)
42. Paulus MP, Geyer MA. A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1991a ; 15: 903-919
43. Paulus MP, Geyer MA. A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology (Berl). 1991b ; 104: 6-16
44. Perry W, Minassian A, Paulus M, Young J, Kincaid M, Ferguson E, et al. A reverse-translational study of dysfunctional exploration in psychiatric disorders: From Mice to Men. Arch Gen Psychiatry. 2009 ; 66: 1072-1080
45. Pierce PA, Peroutka SJ. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl). 1989 ; 97: 118-122 (Pubitemid 19020394)
46. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA. Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology. 2006 ; 31: 2349-2358 (Pubitemid 44607051)
47. Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, et al. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl). 2007 ; 192: 159-170 (Pubitemid 46669211)
48. Sanchez C, Arnt J, Moltzen E. Assessment of relative efficacies of 5-HT1A receptor ligands by means of in vivo animal models. Eur J Pharmacol. 1996 ; 315: 245-254 (Pubitemid 26414269)
49. Sard H, Kumaran G, Morency C, Roth BL, Toth BA, He P, et al. SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 ; 15: 4555-4559 (Pubitemid 41253894)
50. Smith LM, Peroutka SJ. Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav. 1986 ; 24: 1513-1519 (Pubitemid 16066606)
51. Spencer DG, Glaser T, Traber J. Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N- dimethyltryptamine. Psychopharmacology (Berl). 1987 ; 93: 158-166 (Pubitemid 18013050)
52. Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1996 ; 73: 121-124 (Pubitemid 26008771)
53. Tricklebank MD, Forler C, Middlemiss DN, Fozard JR. Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur J Pharmacol. 1985 ; 117: 15-24 (Pubitemid 16204495)
54. Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: Implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2003 ; 28: 170-181
55. Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, et al. Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav. 2001 ; 69: 643-652 (Pubitemid 32758752)
56. Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 2007 ; 32: 1876-1887 (Pubitemid 47258517)
57. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997 ; 16: 357-372 (Pubitemid 27211734)
58. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998 ; 9: 3897-3902 (Pubitemid 29189323)
59. Wing LL, Tapson GS, Geyer MA. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl). 1990 ; 100: 417-425 (Pubitemid 20052435)
60. Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA. The paradox of 5-methoxy-N,N-dimethyltryptamine: An indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav. 2000 ; 65: 75-82 (Pubitemid 30017998)
61. Winter JC, Rice KC, Amorosi DJ, Rabin RA. Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav. 2007 ; 87: 472-480 (Pubitemid 47238403)
62. Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007 ; 21: 50-64 (Pubitemid 46012083)
63. Yamamoto T, Ueki S. Behavioral effects of 2,5-dimethoxy-4- methylamphetamine (DOM) in rats and mice. Eur J Pharmacol. 1975 ; 32: 156-162